Key result
Intracoronary epinephrine significantly reduced the 30-day composite of death or heart failure compared to conventional treatments alone (35.7% vs. 81.25%) in STEMI patients with refractory no-reflow.
Why the study?
The authors sought to compare the efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients experiencing refractory coronary no-reflow during primary PCI.
Does intracoronary epinephrine improve coronary flow and clinical outcomes in STEMI patients with refractory coronary no-reflow during primary PCI?
Observational (n=30)
Does intracoronary epinephrine improve coronary flow and clinical outcomes in STEMI patients with refractory coronary no-reflow during primary PCI?
Absolute Event Rate: 35.7% vs 81.25%
In a proof-of-concept observational study, intracoronary epinephrine improved coronary flow and short-term clinical outcomes in STEMI patients with refractory no-reflow during primary PCI.
No takes yet. Share an insight, caveat, or question.
May support intracoronary epinephrine in refractory no-reflow; hypothesis-generating and requires randomized confirmation before practice change.
Navarese et al. (2020) conducted an observational in ST-elevation myocardial infarction with refractory coronary no-reflow (n=30). Intracoronary epinephrine vs. Conventional treatments alone was evaluated on 30-day composite of death or heart failure. Intracoronary epinephrine significantly reduced the 30-day composite of death or heart failure compared to conventional treatments alone (35.7% vs. 81.25%) in STEMI patients with refractory no-reflow.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: